Skip to content

Multiple Myeloma

US Focus Meeting 2026

📍 Sheraton Boston Hotel, 39 Dalton St, Boston, MA 02199

🗓️ August 14 - 15, 2026

Last Year's Highlights

Dear Colleagues and Friends,

We are delighted to extend our warmest invitation to the Multiple Myeloma Focus Meeting 2026, to be held on August 14 - 15, 2026.  

Centered around the theme “Updating Knowledge & Clinical Practice in 2026” this meeting provides pivotal collaboration aimed at advancing Multiple Myeloma research and patient treatment.  

This meeting presents an opportunity for medical professionals to engage in the exchange of knowledge, expertise, and insights, as well as networking with leading experts. Engage in riveting presentations, participate in thought-provoking debates and roundtable discussions, and connect with peers at informal social gatherings.  

 

Chairs of Multiple Myeloma US Focus Meeting 2026:

Noopur-Raje

Noopur Raje
Massachusetts General Hospital, Boston, MA


Shaji-Kumar

Shaji Kumar
Mayo Clinic, Rochester, MN


Thanks to Our Supporters

Platinum

GSK_Logo
Kite

Gold

BMS_square
Pfizer -Oncology_Signature_Color_CMYK
Regeneron-updated
Legend_biotech_square

Silver

Johnson&Johnson
Sanofi

Agenda & Faculty

August 14, 2026 | Day 1  

08:00 AM
Registration Opens
 
08:45 AM
Welcome and Introduction

Session I: Diagnostic and Disease Monitoring Tools in Myeloma
Moderated by:

Noopur-Raje

Noopur Raje
Massachusetts General Hospital, Boston, MA

Mehmet-K-Samur
Mehmet K. Samur
Dana-Farber Cancer Institute, Boston, MA
09:00 AM
Role of Mass Spectrometry in Screening, Diagnosis, and Disease Monitoring
David-Murray
David L. Murray
Mayo Clinic, Rochester, MN
09:15 AM
Can We Replace FISH Panel with Sequencing?
Mehmet-K-Samur
Mehmet K. Samur
Dana-Farber Cancer Institute, Boston, MA
09:30 AM
MRD Monitoring in MM – Current Approaches
Poy-Theprungsirikul
Poy Theprungsirikul
Dana-Farber Cancer Institute, Boston, MA
09:45 AM
Panel Discussion
10:15 AM
Case Discussion: “Case of diagnosis with FISH and imaging and monitoring with MRD" followed by Q&A
Kevin-Miller
Kevin Miller
Massachusetts General Brigham Hospital, Boston, MA
10:30 AM
Coffee Break and Networking 

Session II: Management of Precursor Conditions
Moderated by:

Shaji-Kumar

Shaji Kumar
Mayo Clinic, Rochester, MN

Natalie-Callander-1
Natalie Callander
UW Health, Madison, WI
10:50 AM
Monoclonal Gammopathy – Diagnosis and Risk Adapted Approach to Monitoring
Natalie-Callander-1
Natalie Callander
UW Health, Madison, WI
11:05 AM
Smoldering Multiple Myeloma – Current Approaches to Management
Tarek-Mouhieddine
Tarek Mouhieddine
Dana-Farber Cancer Institute, Boston, MA
11:20 AM
Monoclonal Gammopathies – When Are They of Clinical Significance?
Shaji-Kumar
Shaji Kumar
Mayo Clinic, Rochester, MN
11:35 AM
Panel Discussion
12:05 PM
Case Discussion: “Smoldering MM Patient" followed by Q&A
Harsh-Parmer
Harsh Parmar
Hackensack Meridian Health, NJ
12:20 PM
Independent Expert Discussion supported by Regeneron
01:05 PM
Lunch Break and Networking

Session III: Other Plasma Cell Disorders
Moderated by:

Shaji-Kumar

Shaji Kumar
Mayo Clinic, Rochester, MN

Anita-DSouza
Anita D’Souza
Medical College of Wisconsin, Wauwatosa, WI
01:55 PM
Novel Therapies in AL
Anita-DSouza
Anita D’Souza
Medical College of Wisconsin, Wauwatosa, WI
02:10 PM
Waldenström Macroglobulinemia
Prashant-Kapoor-1
Prashant Kapoor
Mayo Clinic, Rochester, MN
02:25 PM
Panel Discussion
02:55 PM
Case Discussion: “Waldenstrom’s case” followed by Q&A
Saurabh-Zanwar
Saurabh Zanwar
Mayo Clinic, Rochester, MN
03:10 PM
Coffee Break and Networking 

Session IV: Newly Diagnosed Multiple Myeloma
Moderated by:

Tom-Martin

Tom Martin
UCSF Health, San Francisco, CA

Amrita-Krishnan-1
Amrita Krishnan
City of Hope, Duarte, CA
03:30 PM
Integrating T-Cell Redirection Therapy into Newly Diagnosed MM Treatment
Surbhi-Sidana
Surbhi Sidana
Stanford Medicine, CA
03:45 PM
Does Transplant Have a Role in the Management of Myeloma – Upfront or Later?
Amrita-Krishnan-1
Amrita Krishnan
City of Hope, Duarte, CA
04:00 PM
Defining Frailty and Making Treatment Decisions
Ashley-Rosko
Ashley Rosko
The Ohio State University Comprehensive Cancer Center, Columbus, OH
04:15 PM
Panel Discussion & Take-Home Points from Day 1
04:45 PM
Case Discussion: “Newly Diagnosed MM” followed by Q&A
Benjamin-Puliafito
Benjamin Puliafito
Massachusetts General Hospital, Boston, MA
05:00 PM
Adjourn

August 15, 2026 | Day 2

08:30 AM
Registration Opens

Session V: Individualizing Therapy in Myeloma – Role of Risk Stratification
Moderated by: Prashant Kapoor & Saad Usmani

Prashant-Kapoor-1
Prashant Kapoor
Mayo Clinic, Rochester, MN
Saad-Usmani
Saad Usmani
Memorial Sloan Kettering Cancer Center, New York, NY
09:00 AM
How Do We Adapt Treatment to Baseline
Saad-Usmani
Saad Usmani
Memorial Sloan Kettering Cancer Center, New York, NY
09:15 AM
Integrating Response into Treatment Decisions
Gurbakhash-Kaur
Gurbakhash Kaur
Icahn School of Medicine at Mount Sinai,
New York, NY
09:30 AM
Management of Extramedullary Decisions
Wilson-Gonsalves-1
Wilson Gonsalves
Mayo Clinic, Rochester, MN
09:45 AM
Panel Discussion
10:15 AM
Case Discussion: “High risk patient with EMD” followed by Q&A
Emily-Liang
Emily Liang
Fred Hutchinson Cancer Center, Seattle, WA
10:30 AM
Coffee Break and Networking

Session VI: Management of Initial Relapse: Part 1
Moderated by:

Krina-Patel
Krina Patel
MD Anderson Cancer Center, Houston, TX
Jonathan-Kaufman
Jonathan Kaufman
Emory Winship Cancer Institute, Atlanta, GA
10:50 AM
When Should We Start Treatment for Relapse?
Jonathan-Kaufman
Jonathan Kaufman
Emory Winship Cancer Institute, Atlanta, GA
11:05 AM
Treatment at First Relapse – IMiD-PI-anti- CD38 Based Combinations Should Be First Choice
Binod-Dhakal
Binod Dhakal
Medical College of Wisconsin, Wauwatosa, WI
11:20 AM
CAR-T Should Be the Treatment of Choice
Doris-Hansen-1
Doris Hansen
Moffitt Cancer Center, FL
13:35 AM
Panel Discussion
12:05 PM
Lunch Break and Networking

Session VII: Management of Initial Relapse: Part 2
Moderated by:

Noopur-Raje

Noopur Raje
Massachusetts General Hospital, Boston, MA

Surbhi-Sidana
Surbhi Sidana
Stanford Medicine, CA
12:55 PM
Bispecific Antibody Should Be the Treatment of Choice
Krina-Patel
Krina Patel
MD Anderson Cancer Center, Houston, TX
01:10 PM
ADC Should Be the Treatment Choice
Nisha-Joseph
Nisha Joseph
Emory Winship Cancer Institute, Atlanta, GA
01:25 PM
Panel Discussion
01:55 PM
Case Discussion: “Case for Bispecific antibody” followed by Q&A
Narsis-Attar
Narsis Attar
Dana-Farber Cancer Institute, Boston, MA
02:10 PM
Coffee Break and Networking

Session VIII: Management of Late Relapse
Moderated by:

Joshua-Richter
Joshua Richter
Icahn School of Medicine at Mount Sinai, New York, NY
Doris-Hansen-1
Doris Hansen
Moffitt Cancer Center, FL
02:30 PM
Novel Approaches to TCE Therapies - Bispecifics and Trispecifics
Andrew-Yee
Andrew Yee
Massachusetts General Hospital, Boston, MA
02:45 PM
Novel CAR-T Cell Approaches
Tom-Martin
Tom Martin
UCSF Health, San Francisco, CA
03:00 PM
Targeted Therapies in MM - Moving Beyond Immunotherapy
Joshua-Richter
Joshua Richter
Icahn School of Medicine at Mount Sinai, New York, NY
03:15 PM
Panel Discussion & Take-Home Points from Day 2
03:45 PM
Case Discussion: “Patient with late relapse-triple class refractory, post BCMA Redirection therapy.” followed by Q&A
Nadine-Abdallah
Nadine Abdallah
Mayo Clinic, Rochester, MN
04:00 PM
Adjourn

Freya Symons
Project Manager

How long has Freya Symons been in the business?

Freya Symons has been with MD Education since 2025. 

About Freya Symons

As a Project Manager at MD Education’s Wigan office, I support the smooth delivery of educational events through effective coordination, organisation, and communication. With a strong background in project-based work and a degree in Business Management and Marketing, I take pride in my attention to detail and ability to build positive working relationships. I am committed to supporting project teams and contributing to the delivery of high-quality projects. For me, seeing projects develop from initial ideas to successful delivery is what makes the role so rewarding.

Freya-Symons-Web